Taxonomy

CMTA Alliance Partner, Applied Therapeutics, Announces Positive 12-Month Results in its Ongoing INSPIRE Phase III Trial for CMT-SORD

In a statement released on February 15, 2024, by Charcot-Marie-Tooth

Read More

The CMTA Appoints Professor Charlotte Sumner, M.D., to its Scientific Advisory Board

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth

Read More

CMTA Awards Over Half a Million Dollars to Fuel Research in Demyelinating Forms of CMT

Multisite and multiyear collaborative project led by a team of

Read More

2023 CMTA-STAR Celebrating our Collective Achievements

Significant Research Investment Made in 2023: We are excited to

Read More

ToolGen CMT1A Treatment Receives Orphan Drug Designation

CMTA Alliance Partner ToolGen announced December 18, 2023 that it

Read More

Pharnext Announces Disappointing Results for CMT1A Drug Trial PXT-3003

Published: December 11, 2023 French biopharmaceutical company Pharnext SA announced

Read More

Novartis Secures $1.3B Deal for CMT Treatment CKD-510

Novartis is making significant strides in the field of Charcot-Marie-Tooth

Read More

Therapeutic Inactivation of CMT2 Disease Alleles with CRISPR

New technologies in gene editing such as CRISPR/Cas9 present a

Read More

CMTA Announces Participation in Seed Extension Round for Armatus Bio for Novel CMT1A Gene Therapy

First Investment from CMTA’s New Venture Philanthropy Arm The Charcot-Marie-Tooth

Read More

CMTA Appoints Biotech Industry Veteran Suzanne Bruhn, PhD as New CEO

GLENOLDEN, Pa., November 6, 2023 – The Charcot-Marie-Tooth Association announced

Read More